Inclusion Criteria:  Age 45-70, gender unlimited (including 45 and 70); diagnoses in accordance with the confirmed and proposed ALS diagnostic standards ofthe Revised World Federation of Neurology (1998); The duration of disease from onset to randomization of subjects is less than 2 years; Before randomization, ALSFRS-R scores were ≥2 points, and respiratory function items were 4 points; ALSFRS-R decreased by 1-4 points in screening period 3A (≥1 and lt; 4); Random pre-respiratory function Forced Vital Capacity (%FVC) ≥80%; Understand and abide by the test procedures, participate voluntarily, and sign the informed consent (the informed consent should be signed by the person or the guardian voluntarily).  Exclusion Criteria:  Familial ALS (judged by family history); Patients with significant cognitive impairment (MMSE: illiteracy group &lt; 19 points, elementary school. 22 points, S26 points in the junior high school and above group (more than 8 years of education); obvious dysphagia; Severe renal insufficiency: creatinine clearance. 30 mL/min (Cockcroft-Gault formula), or other known severe renal insufficiency; Severe liver function impairment: ALT, AST&GT; 3 times the upper limit of normal value, or other known liver diseases such as acute or chronic active hepatitis, cirrhosis, etc.; In the screening stage, patients with heart failure who developed acute myocardial infarction or underwent interventional therapy within the last 6 months (grade II1-IV according to NYHA); Complicated with malignant tumors, serious diseases of blood, digestion or other systems. Allergic to experimental drugs or ligustrazine; Pregnancy and lactation; Participated in, or is participating in, other clinical trials within 30 days prior to screening; The investigator did not consider it appropriate to participate in this study.